Close Menu

NEW YORK (GenomeWeb) – Foundation Medicine and the Sarah Cannon Research Institute are collaborating to use genomic profiling as part of clinical trials, the organizations said today.

Under the partnership, researchers can use Foundation Medicine's FoundationOne assay for solid tumors, FoundationOne Heme for hematologic cancers, and FoundationACT for liquid biopsy analysis to identify patients eligible for Sarah Cannon's clinical studies.

Sarah Cannon will also integrate Foundation's decision support portal, called Interactive Cancer Explorer, across its network.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Nov
14
Sponsored by
Qiagen

This webinar will discuss some of the issues laboratories face when transitioning to next-generation sequencing, and the key features to be considered for a successful implementation in routine testing.

Dec
02
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.